Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy (HEMT), including elexacaftor/tezacaftor/ivacaftor (ETI), is now approved for more than 90% of adults with the genetic disorder cystic fibrosis. The gene discussed is CFTR; the disease is hereditary disease.